Super-Rich Biohackers: Tim Gurner & Elite Longevity Protocols
The world of biohacking has evolved from a fringe movement into a billion-dollar industry embraced by the ultra-wealthy, with Australian property mogul Tim Gurner becoming the latest high-profile figure to publicly discuss his extensive anti-aging regimen. According to recent reports from The Guardian, Gurner and a growing cohort of super-rich “grinders” are investing astronomical sums […]
Common Supplement Reverses Aging in Groundbreaking Study
In a development that has captured the attention of the biohacking and longevity optimization community, researchers have documented the first successful reversal of premature aging in humans using a widely available supplement. The landmark clinical trial, recently reported by ScienceDaily, represents a significant milestone in the quest for age-reversal interventions that Tony Huge and the […]
UBX1325: The Senolytic That Nearly Proved It
UBX1325 (Foselutoclax): The Senolytic That Got Closest to Proving It — and What It Still Didn’t Prove Quick Summary UBX1325 (foselutoclax) is an investigational small-molecule BCL-xL inhibitor injected directly into the eye. It kills senescent cells by blocking the survival protein they lean on. It was tested against a real drug in a real head-to-head […]
Obicetrapib: The CETP Inhibitor That Came Back
Obicetrapib: The CETP Inhibitor That Came Back From the Dead Quick Summary Obicetrapib is an investigational once-daily oral CETP inhibitor, not approved for general prescription anywhere. Regulatory decisions in Europe, the UK and Switzerland were expected in the second half of 2026; there is no US approval. The CETP class was written off twice. Torcetrapib […]
Zoledronic Acid: Bone Density and the Geroprotector Case
Zoledronic Acid: Bone Density, and the Case For and Against It as a Geroprotector Quick Summary A nitrogen-containing bisphosphonate given as an IV infusion by a clinician. It inhibits farnesyl pyrophosphate synthase in osteoclasts, shutting down bone resorption long after a single dose. The fracture data are strong: in HORIZON-PFT, three annual infusions cut vertebral […]
Canakinumab and CANTOS: What Targeting IL-1B Achieved
Canakinumab and CANTOS: What Happened When Someone Finally Tested “Inflammaging” Head-On Quick Summary Canakinumab is a monoclonal antibody that neutralizes interleukin-1β (IL-1β), the cytokine released downstream of the NLRP3 inflammasome. It is FDA-approved for rare autoinflammatory conditions and gout flares — not for cardiovascular prevention or longevity. CANTOS randomized 10,061 post-heart-attack patients with hsCRP ≥2 […]
Low-Dose Colchicine for Heart Risk: What Trials Show
Low-Dose Colchicine for Heart Risk: What Trials Show Quick Summary June 2023: the FDA approved colchicine 0.5 mg (Lodoco) to reduce risk of MI, stroke, coronary revascularization and cardiovascular death in adults with atherosclerotic disease or multiple risk factors — the first anti-inflammatory approved for that purpose. LoDoCo2 (5,522 chronic coronary disease patients): primary composite […]
Boulder Biohacking Boom: Tony Huge’s Influence Expands
The wellness capital of America is experiencing a transformation that advocates like Tony Huge have been predicting for years. According to recent reports from Axios, Boulder, Colorado’s already-thriving wellness scene is receiving what industry insiders are calling a “biohacking boost” — a shift that aligns perfectly with the enhancement protocols and optimization strategies that Tony […]
Calocurb Research: Muscle Preservation During Weight Loss
The bodybuilding and biohacking communities have long grappled with one of the most challenging aspects of physique optimization: how to lose body fat while preserving hard-earned muscle mass. Recent research emerging from studies on Calocurb, a natural supplement derived from hops flower extract, suggests a potential solution to this age-old dilemma. According to a report […]
BPC-157: The Body Protection Compound Protocol for Tendon and Gut Repair
BPC-157 is a synthetic pentadecapeptide that drives angiogenesis at injury sites via VEGFR2 upregulation. Real protocol, real dosing, real results from Tony Huge.